Induction of Tp and DPD Expression by Docetaxel and Doxifluridine (5'-Dfur) in Gastric Cancer

Okitsu, Hiroshi; Umemoto, Atsushi; Honda, Junko; Okitsu, Natsu; Seike, Junichi; Tanida, Nobuyuki; Monden, Yasumasa

doi:10.3919/jjsa.65.587

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DPD alteration in malignant tumors induced by docetaxel has not been previously reported, with the exception of one report of the investigation of the induction of DPD expression by docetaxel in gastric cancer. However, the data resulted in no induction of DPD expression (38). Our results regarding DPD activity, however, demonstrate a significant down-regulation upon the administration of docetaxel.…”

Section: ------------------------------------------------------------contrasting

confidence: 58%

Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice

Suto¹,

Kubota²,

Fukushima³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

In vivo experiments were performed on breast cancer xenografts to examine whether the combination therapy with S-1, an oral dihydrouracil dehydrogenase (DPD) inhibitory fluoropyrimidine, plus docetaxel functions as an additive/synergistic modulator in tumor growth. The human breast cancer xenograft, MDA-MB-435SHM, was inoculated into SCID female mice. The tumor growth and thymidylate synthase (TS)/DPD activity of tumors treated with the agents were investigated. The T/C value (relative mean tumor weight of the treated group/relative tumor weight of the control group) of the group treated with docetaxel, S-1 and combination therapy were 45.3, 63.1 and 29.8%, respectively; suggesting the positive antitumor effects of the combination therapy in particular. In addition, significant down-regulation of DPD activity was also observed in the tumors treated with S-1, docetaxel and their combination. Down-regulation of the DPD activity of the tumors is also considered to be correlated with the antitumor effect of the treated groups, suggesting its influence on the synergistic effect of the combination therapy.

show abstract

Section: ------------------------------------------------------------contrasting

confidence: 58%

Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice

Suto¹,

Kubota²,

Fukushima³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Thymidine phosphorylase (TP) is the fi rst enzyme in the metabolic activation pathway. In our department, we reported that TP expression was induced in cancer tissue by the administration of docetaxel (40 mg/body), whereas TP expression in normal mucosa was unchanged in patients with gastric cancer [23]. Furthermore, TP expression was signifi cantly higher in esophageal cancer than in gastric cancer and colorectal cancer in our studies.…”

Section: Discussionmentioning

confidence: 72%

“…Therefore, concomitant use of docetaxel and 5-FU can be expected to synergistically potentiate individual antitumor effects in esophageal cancer. The schedule of this regimen for the induction of TP expression was 40 mg/body docetaxel [23] and triweekly regimen (75 mg/m 2 ) divided into 3 weeks [24]. In terms of the cycle number of preoperative DFP, the majority of patients underwent only one cycle before esophagectomy.…”

Section: Discussionmentioning

confidence: 99%

Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus

et al. 2010

Self Cite

View full text Add to dashboard Cite

Background. Docetaxel is a powerful anticancer agent for esophageal cancer. Preoperative combined chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fl uorouracil (DFP) followed by surgery is expected to improve the survival of patients with resectable esophageal squamous cell carcinoma. Methods. Clinical stage II/III squamous cell carcinoma patients who received DFP followed by esophagectomy (NAC group, n = 13) were compared retrospectively with patients who received surgery without preoperative DFP (Surgery group, n = 12). Not only the effi cacy and toxicity of initial chemotherapy but also morbidity and survival after esophagectomy were assessed. Results. Of 13 patients, the overall response rate was 92.3%; 30.8% (4/13) patients had CR, 61.5% (8/13) PR, 7.7% (1/13) SD, and 0 (0/13) PD. The 4 patients who achieved a pathological complete response (pCR) included 1 with cT4N1M0, 2 with cT3N1M0, and 1 with cT3N0M0. More than grade 3 toxicity of neutropenia and stomatitis occurred in 15.4% and 23.1% of patients, respectively. Leakage was 23.1% in the NAC group and 8.3% in the Surgery group. No treatment-related deaths occurred in the NAC group. Conclusions. This regimen as preoperative chemotherapy seemed to provide a high response rate and a favorable survival benefi t with acceptable toxicity and morbidity. To validate the clinical signifi cance of this protocol, a randomized trial is essential.

show abstract

Preoperative chemoradiotherapy with docetaxel, doxifluridine, and low-dose cisplatin for stage II/III squamous cell carcinoma of the esophagus

et al. 2014

View full text Add to dashboard Cite

Induction of Tp and DPD Expression by Docetaxel and Doxifluridine (5'-Dfur) in Gastric Cancer

Cited by 3 publications

References 7 publications

Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice

Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice

Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus

Preoperative chemoradiotherapy with docetaxel, doxifluridine, and low-dose cisplatin for stage II/III squamous cell carcinoma of the esophagus

Contact Info

Product

Resources

About